Literature DB >> 30843350

Laparoscopic pancreaticoduodenectomy for remnant pancreatic recurrence after laparoscopic distal pancreatectomy and hepatectomy for greater omentum leiomyosarcoma.

Yoichi Nakagawa1, Yasuyuki Fukami1, Tohru Harada1, Atsuyuki Maeda1, Yuichi Takayama1, Takamasa Takahashi1, Masahito Uji1, Yuji Kaneoka1.   

Abstract

Laparoscopic pancreatic surgery is one of the most difficult procedures, and the adoption of laparoscopic pancreaticoduodenectomy has been limited. The application of laparoscopic surgery has extended to advance cancer, but there have been no reports of laparoscopic pancreaticoduodenectomy after laparoscopic liver resection and distal pancreatectomy. In the present case, a 67-year-old woman was diagnosed with remnant pancreatic recurrence of metastatic greater omentum leiomyosarcoma. She had previously undergone laparoscopic distal pancreatectomy and left lateral liver sectionectomy in 2016. We performed laparoscopic subtotal stomach-preserving pancreaticoduodenectomy in June 2017. The operation time was 274 minutes, and the estimated blood loss was 50 mL. There were no postoperative complications. In summary, laparoscopic pancreaticoduodenectomy is a safe and feasible procedure for a patient who had previously undergone pancreas and liver surgery.
© 2019 Japan Society for Endoscopic Surgery, Asia Endosurgery Task Force and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  laparoscopic pancreaticoduodenectomy; leiomyosarcoma; remnant pancreatic recurrence

Mesh:

Year:  2019        PMID: 30843350     DOI: 10.1111/ases.12695

Source DB:  PubMed          Journal:  Asian J Endosc Surg        ISSN: 1758-5902


  2 in total

1.  Application of a surgical nursing cooperation program in laparoscopic pancreaticoduodenectomy.

Authors:  Yihong Qiu; Xia Ouyang; Min Luo; Lijun Feng; Chulian Zheng; Guolin Li
Journal:  Gland Surg       Date:  2020-10

Review 2.  Is Laparoscopic Pancreaticoduodenectomy Feasible for Pancreatic Ductal Adenocarcinoma?

Authors:  Chang Moo Kang; Woo Jung Lee
Journal:  Cancers (Basel)       Date:  2020-11-18       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.